Racial differences in primary cytogenetic abnormalities in multiple myeloma: A multi-center study

A. J. Greenberg, S. Philip, A. Paner, S. Velinova, A. Badros, R. Catchatourian, R. Ketterling, R. A. Kyle, Shaji K Kumar, Celine M Vachon, S Vincent Rajkumar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We examined four clinically assessed cytogenetic subtypes (t(11;14), t(4;14), monosomy 13/del13q and monosomy 17/del17p in 292 black patients with newly diagnosed multiple myeloma (MM) from four medical centers, who had fluorescent in situ hybridization testing results available in their medical records. We then compared the prevalence of these abnormalities with a previously characterized Mayo Clinic cohort of 471 patients with MM. We found a significant difference in the prevalence of the t(11;14) immunoglobulin heavy chain (IgH) translocation between blacks and whites, 6.5% versus 17.6%, respectively, Po0.0001. Blacks also had lower rates of the t(4;14) IgH translocation, (5.5% versus 10%); monosomy 13/del13q (29.1 versus 49.3%); and monosomy 17/ del17p (7.9% versus 13%). Consequently, 63.4% of blacks versus 34.6% of whites did not have any of the four abnormalities that we studied, Po0.001. As almost all MM is associated with either an IgH translocation or trisomies, we hypothesize that MM in blacks is associated with either excess prevalence of either the trisomic (hyperdiploid) form of MM or an IgH translocation besides t(11;14) or t (4;14). We conclude that there are significant differences in the cytogenetic subtypes of MM that occur in blacks and whites.

Original languageEnglish (US)
Pages (from-to)e271
JournalBlood Cancer Journal
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Multiple Myeloma
Chromosome Aberrations
Monosomy
Immunoglobulin Heavy Chains
Cytogenetics
Polyploidy
Trisomy
Fluorescence In Situ Hybridization
Medical Records

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Racial differences in primary cytogenetic abnormalities in multiple myeloma : A multi-center study. / Greenberg, A. J.; Philip, S.; Paner, A.; Velinova, S.; Badros, A.; Catchatourian, R.; Ketterling, R.; Kyle, R. A.; Kumar, Shaji K; Vachon, Celine M; Rajkumar, S Vincent.

In: Blood Cancer Journal, Vol. 5, No. 1, 01.01.2015, p. e271.

Research output: Contribution to journalArticle

Greenberg, AJ, Philip, S, Paner, A, Velinova, S, Badros, A, Catchatourian, R, Ketterling, R, Kyle, RA, Kumar, SK, Vachon, CM & Rajkumar, SV 2015, 'Racial differences in primary cytogenetic abnormalities in multiple myeloma: A multi-center study', Blood Cancer Journal, vol. 5, no. 1, pp. e271. https://doi.org/10.1038/bcj.2014.91
Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R et al. Racial differences in primary cytogenetic abnormalities in multiple myeloma: A multi-center study. Blood Cancer Journal. 2015 Jan 1;5(1):e271. https://doi.org/10.1038/bcj.2014.91
Greenberg, A. J. ; Philip, S. ; Paner, A. ; Velinova, S. ; Badros, A. ; Catchatourian, R. ; Ketterling, R. ; Kyle, R. A. ; Kumar, Shaji K ; Vachon, Celine M ; Rajkumar, S Vincent. / Racial differences in primary cytogenetic abnormalities in multiple myeloma : A multi-center study. In: Blood Cancer Journal. 2015 ; Vol. 5, No. 1. pp. e271.
@article{a44ef33ddd954239a17fe5506439df40,
title = "Racial differences in primary cytogenetic abnormalities in multiple myeloma: A multi-center study",
abstract = "We examined four clinically assessed cytogenetic subtypes (t(11;14), t(4;14), monosomy 13/del13q and monosomy 17/del17p in 292 black patients with newly diagnosed multiple myeloma (MM) from four medical centers, who had fluorescent in situ hybridization testing results available in their medical records. We then compared the prevalence of these abnormalities with a previously characterized Mayo Clinic cohort of 471 patients with MM. We found a significant difference in the prevalence of the t(11;14) immunoglobulin heavy chain (IgH) translocation between blacks and whites, 6.5{\%} versus 17.6{\%}, respectively, Po0.0001. Blacks also had lower rates of the t(4;14) IgH translocation, (5.5{\%} versus 10{\%}); monosomy 13/del13q (29.1 versus 49.3{\%}); and monosomy 17/ del17p (7.9{\%} versus 13{\%}). Consequently, 63.4{\%} of blacks versus 34.6{\%} of whites did not have any of the four abnormalities that we studied, Po0.001. As almost all MM is associated with either an IgH translocation or trisomies, we hypothesize that MM in blacks is associated with either excess prevalence of either the trisomic (hyperdiploid) form of MM or an IgH translocation besides t(11;14) or t (4;14). We conclude that there are significant differences in the cytogenetic subtypes of MM that occur in blacks and whites.",
author = "Greenberg, {A. J.} and S. Philip and A. Paner and S. Velinova and A. Badros and R. Catchatourian and R. Ketterling and Kyle, {R. A.} and Kumar, {Shaji K} and Vachon, {Celine M} and Rajkumar, {S Vincent}",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/bcj.2014.91",
language = "English (US)",
volume = "5",
pages = "e271",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Racial differences in primary cytogenetic abnormalities in multiple myeloma

T2 - A multi-center study

AU - Greenberg, A. J.

AU - Philip, S.

AU - Paner, A.

AU - Velinova, S.

AU - Badros, A.

AU - Catchatourian, R.

AU - Ketterling, R.

AU - Kyle, R. A.

AU - Kumar, Shaji K

AU - Vachon, Celine M

AU - Rajkumar, S Vincent

PY - 2015/1/1

Y1 - 2015/1/1

N2 - We examined four clinically assessed cytogenetic subtypes (t(11;14), t(4;14), monosomy 13/del13q and monosomy 17/del17p in 292 black patients with newly diagnosed multiple myeloma (MM) from four medical centers, who had fluorescent in situ hybridization testing results available in their medical records. We then compared the prevalence of these abnormalities with a previously characterized Mayo Clinic cohort of 471 patients with MM. We found a significant difference in the prevalence of the t(11;14) immunoglobulin heavy chain (IgH) translocation between blacks and whites, 6.5% versus 17.6%, respectively, Po0.0001. Blacks also had lower rates of the t(4;14) IgH translocation, (5.5% versus 10%); monosomy 13/del13q (29.1 versus 49.3%); and monosomy 17/ del17p (7.9% versus 13%). Consequently, 63.4% of blacks versus 34.6% of whites did not have any of the four abnormalities that we studied, Po0.001. As almost all MM is associated with either an IgH translocation or trisomies, we hypothesize that MM in blacks is associated with either excess prevalence of either the trisomic (hyperdiploid) form of MM or an IgH translocation besides t(11;14) or t (4;14). We conclude that there are significant differences in the cytogenetic subtypes of MM that occur in blacks and whites.

AB - We examined four clinically assessed cytogenetic subtypes (t(11;14), t(4;14), monosomy 13/del13q and monosomy 17/del17p in 292 black patients with newly diagnosed multiple myeloma (MM) from four medical centers, who had fluorescent in situ hybridization testing results available in their medical records. We then compared the prevalence of these abnormalities with a previously characterized Mayo Clinic cohort of 471 patients with MM. We found a significant difference in the prevalence of the t(11;14) immunoglobulin heavy chain (IgH) translocation between blacks and whites, 6.5% versus 17.6%, respectively, Po0.0001. Blacks also had lower rates of the t(4;14) IgH translocation, (5.5% versus 10%); monosomy 13/del13q (29.1 versus 49.3%); and monosomy 17/ del17p (7.9% versus 13%). Consequently, 63.4% of blacks versus 34.6% of whites did not have any of the four abnormalities that we studied, Po0.001. As almost all MM is associated with either an IgH translocation or trisomies, we hypothesize that MM in blacks is associated with either excess prevalence of either the trisomic (hyperdiploid) form of MM or an IgH translocation besides t(11;14) or t (4;14). We conclude that there are significant differences in the cytogenetic subtypes of MM that occur in blacks and whites.

UR - http://www.scopus.com/inward/record.url?scp=84927748520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927748520&partnerID=8YFLogxK

U2 - 10.1038/bcj.2014.91

DO - 10.1038/bcj.2014.91

M3 - Article

C2 - 25555162

AN - SCOPUS:84927748520

VL - 5

SP - e271

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 1

ER -